AGN Notification regarding unquoted securities - AGN 30/11/22 download Created with Sketch. 28.22KB Share AGN Phase 1 Clinical Trial Progress Update 25/11/22 PRICE SENSITIVE download Created with Sketch. 254.11KB Share AGN AGM Presentation 25/11/22 download Created with Sketch. 1.11MB Share AGN Results of Annual General Meeting 25/11/22 download Created with Sketch. 244.5KB Share AGN Safety Review Committee Approves Third Cohort Commencement 18/11/22 PRICE SENSITIVE download Created with Sketch. 216.54KB Share AGN Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial 07/11/22 PRICE SENSITIVE download Created with Sketch. 190.99KB Share AGN Safety Review Committee Approves Second Cohort 02/11/22 PRICE SENSITIVE download Created with Sketch. 194.92KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 31/10/22 PRICE SENSITIVE download Created with Sketch. 384.27KB Share AGN No Serious Safety Issues Observed in First Cohort 26/10/22 PRICE SENSITIVE download Created with Sketch. 189.76KB Share AGN Notice of Annual General Meeting/Proxy Form 21/10/22 download Created with Sketch. 627.57KB Share AGN Investor Presentation 20/10/22 download Created with Sketch. 2.7MB Share AGN First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007 17/10/22 PRICE SENSITIVE download Created with Sketch. 190.48KB Share AGN Argenica Receives $1.38m R&D Tax Incentive Cash Refund 04/10/22 PRICE SENSITIVE download Created with Sketch. 171.67KB Share AGN Further Positive Preclinical Results for ARG-007 In HIE 29/09/22 PRICE SENSITIVE download Created with Sketch. 486.34KB Share AGN Date of AGM and Closing Date for Director Nominations 16/09/22 download Created with Sketch. 186.81KB Share AGN Phase 1 Clinical Trial Summary 08/09/22 download Created with Sketch. 202.58KB Share AGN Argenica Receives Ethics Approval To Commence Phase 1 Trial 07/09/22 PRICE SENSITIVE download Created with Sketch. 229.38KB Share AGN Appendix 4G & Corporate Governance Statement 23/08/22 download Created with Sketch. 508.22KB Share AGN Appendix 4E & Annual Report 30 June 2022 23/08/22 PRICE SENSITIVE download Created with Sketch. 1.31MB Share AGN Ethics Application Submitted for Phase 1 Trial 11/08/22 download Created with Sketch. 218.25KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 29/07/22 PRICE SENSITIVE download Created with Sketch. 453.67KB Share AGN Clinical Advisory Committee Appointment 11/07/22 download Created with Sketch. 190.38KB Share AGN Notification regarding unquoted securities - AGN 11/07/22 download Created with Sketch. 28.11KB Share AGN Peer Reviewed Paper Published on Preclinical Safety Study 07/07/22 PRICE SENSITIVE download Created with Sketch. 212.52KB Share AGN Investor Presentation - Updated 17/06/22 download Created with Sketch. 3.41MB Share AGN Change of Director's Interest Notice x2 16/06/22 download Created with Sketch. 313.37KB Share AGN Investor Presentation 14/06/22 download Created with Sketch. 3.34MB Share AGN Notification regarding unquoted securities - AGN 10/06/22 download Created with Sketch. 383.34KB Share AGN Cleansing Notice 10/06/22 download Created with Sketch. 172.3KB Share AGN Application for quotation of securities - AGN 10/06/22 download Created with Sketch. 24.82KB Share AGN Proposed issue of securities - AGN 03/06/22 download Created with Sketch. 27.7KB Share AGN Proposed issue of securities - AGN 03/06/22 download Created with Sketch. 28.62KB Share AGN Argenica Successfully Completes $5.5m Placement 03/06/22 PRICE SENSITIVE download Created with Sketch. 296.62KB Share AGN Trading Halt 01/06/22 PRICE SENSITIVE download Created with Sketch. 621.25KB Share AGN Successful Completion of Final Pre-Clinical PK Study 19/05/22 PRICE SENSITIVE download Created with Sketch. 228.98KB Share AGN GLP Safety Studies Successfully Completed 05/05/22 PRICE SENSITIVE download Created with Sketch. 223.97KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 29/04/22 PRICE SENSITIVE download Created with Sketch. 541.52KB Share AGN Maximum Tolerated Dose Successfully Established in Studies 26/04/22 PRICE SENSITIVE download Created with Sketch. 213.15KB Share AGN Initial Director's Interest Notice 04/04/22 download Created with Sketch. 266.18KB Share AGN Argenica Appoints CEO Dr Liz Dallimore Managing Director 04/04/22 PRICE SENSITIVE download Created with Sketch. 230.49KB Share AGN Positive Preclincal Data on Efficacy in New Indication 30/03/22 PRICE SENSITIVE download Created with Sketch. 502.97KB Share AGN Peer Reviewed Paper Published on Preclinical Study 21/03/22 PRICE SENSITIVE download Created with Sketch. 198.67KB Share AGN Investor Presentation 16/03/22 PRICE SENSITIVE download Created with Sketch. 2.54MB Share AGN Change of Director's Interest Notice 28/02/22 download Created with Sketch. 329.95KB Share AGN Successful Completion of Final GLP Genotoxicity Studies 24/02/22 PRICE SENSITIVE download Created with Sketch. 242.32KB Share AGN Half Yearly Report and Accounts 22/02/22 PRICE SENSITIVE download Created with Sketch. 818.74KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 27/01/22 PRICE SENSITIVE download Created with Sketch. 473.11KB Share AGN Preliminary Pre-Clinical Tox Studies Successfully Completed 24/01/22 PRICE SENSITIVE download Created with Sketch. 259.66KB Share AGN Argenica Appoints Head of Clinical Development 13/01/22 download Created with Sketch. 187.08KB Share AGN Notification regarding unquoted securities - AGN 13/01/22 download Created with Sketch. 28.43KB Share AGN Application for quotation of securities - AGN 31/12/21 download Created with Sketch. 24.23KB Share AGN Application for quotation of securities - AGN 17/12/21 download Created with Sketch. 24.25KB Share AGN Release of Restricted Securities from Escrow 10/12/21 download Created with Sketch. 190.15KB Share AGN Argenica to be Granted Patent Protection in the US 09/12/21 PRICE SENSITIVE download Created with Sketch. 230.84KB Share AGN Results of Annual General Meeting 17/11/21 download Created with Sketch. 240.81KB Share AGN AGM Presentation 17/11/21 download Created with Sketch. 2.77MB Share AGN Positive Preclinical Data for ARG-007 Neuroprotection in HIE 03/11/21 PRICE SENSITIVE download Created with Sketch. 601.67KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 28/10/21 PRICE SENSITIVE download Created with Sketch. 444.49KB Share AGN Investor Presentation 27/10/21 download Created with Sketch. 2.94MB Share AGN Phase 1 Clinical Trial Overview & Roadmap 18/10/21 PRICE SENSITIVE download Created with Sketch. 4.03MB Share AGN Notice of Annual General Meeting/Proxy Form 15/10/21 download Created with Sketch. 556.91KB Share AGN Application for quotation of securities - AGN 14/10/21 download Created with Sketch. 24.24KB Share AGN Release of Restricted Securities from Escrow 04/10/21 download Created with Sketch. 190.44KB Share AGN Argenica Partners With Linear For Phase 1 Clinical Trial 30/09/21 PRICE SENSITIVE download Created with Sketch. 263.09KB Share AGN Date of AGM & Closing Date for Director Nominations 21/09/21 download Created with Sketch. 252.21KB Share AGN Argenica Achieves Manufacturing Milestones 14/09/21 PRICE SENSITIVE download Created with Sketch. 414.59KB Share AGN Appendix 4G & Corporate Governance Statement 27/08/21 download Created with Sketch. 512.45KB Share AGN Appendix 4E & Annual Report 30 June 2021 27/08/21 PRICE SENSITIVE download Created with Sketch. 1.15MB Share AGN Appendix 3G 11/08/21 download Created with Sketch. 382.99KB Share AGN Proposed issue of securities - AGN 05/08/21 download Created with Sketch. 25.72KB Share AGN Issue of Options 05/08/21 download Created with Sketch. 300.19KB Share AGN Quarterly Activities/Appendix 4C Cash Flow Report 29/07/21 PRICE SENSITIVE download Created with Sketch. 505.58KB Share AGN Grant Secured to Advance Pre-Clinical Studies Of ARG-007 21/07/21 PRICE SENSITIVE download Created with Sketch. 305.39KB Share AGN Study Additional Information 13/07/21 PRICE SENSITIVE download Created with Sketch. 203.18KB Share AGN Study Shows ARG-007 Does Not Degrade 12/07/21 PRICE SENSITIVE download Created with Sketch. 327.58KB Share AGN Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study 01/07/21 PRICE SENSITIVE download Created with Sketch. 249.45KB Share AGN Change of Registered Office 30/06/21 download Created with Sketch. 182.32KB Share AGN Investor Presentation 16/06/21 download Created with Sketch. 3.29MB Share AGN Argenica Commences Trading on ASX 11/06/21 download Created with Sketch. 436.8KB Share AGN Becoming a substantial holder 09/06/21 download Created with Sketch. 152.77KB Share AGN Becoming a substantial holder 09/06/21 download Created with Sketch. 309.2KB Share AGN Initial Director's Interest Notice x4 09/06/21 download Created with Sketch. 268.1KB Share AGN Confirmation Statements 09/06/21 download Created with Sketch. 246.09KB Share AGN Top 20 Holders 09/06/21 download Created with Sketch. 11.75KB Share AGN Distribution Schedule 09/06/21 download Created with Sketch. 9.75KB Share AGN Securities Trading Policy 09/06/21 download Created with Sketch. 145.8KB Share AGN Corporate Governance Statement 09/06/21 download Created with Sketch. 279.64KB Share AGN Employee Securities Incentive Plan 09/06/21 download Created with Sketch. 583.05KB Share AGN Interim Report for the period ended 31 December 2020 09/06/21 download Created with Sketch. 559.16KB Share AGN Annual Report for period from incorporation to 30 June 2020 09/06/21 download Created with Sketch. 644.64KB Share AGN Constitution 09/06/21 download Created with Sketch. 794.21KB Share AGN Prospectus 09/06/21 download Created with Sketch. 4.83MB Share AGN Appendix 1A & Information Form and Checklist 09/06/21 download Created with Sketch. 350.3KB Share AGN ASX Notice - Admission to Official List 09/06/21 download Created with Sketch. 90.16KB Share AGN Supplementary Prospectus 03/05/11 download Created with Sketch. 32.04KB Share AGN Anagen Limited Prospectus 15/12/10 download Created with Sketch. 4.94MB Share